Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO-Breast-Cancer-2021-1000x250

Platinum Sponsors

Daiichi-Sanyko

SL-Daiichi-Sankyo

With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people.

Pfizer Oncology

SL-Pfizer-Oncology

At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of patients. Today, Pfizer Oncology has an industry-leading portfolio of 23 approved innovative cancer medicines and biosimilars across more than 30 indications, including breast, genitourinary, colorectal, blood and lung cancers, as well as melanoma. 

Seagen

SL-Seagen

Seagen is a global biotechnology company that discovers, develops, and commercializes medicines for cancer. The company has a pipeline of therapies at various stages of preclinical testing, clinical testing, and development.

Gold Sponsors

Lilly

SL-Lilly

Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work.

Novartis Oncology

SL-Novartis

Novartis is reimagining medicine to improve people’s lives. We use innovative science and digital technologies to create transformative treatments. Novartis products reach more than 800 million people globally and we are finding innovative ways to expand access to our medicines. About 109,000 people of more than 145 nationalities work at Novartis.

MSD Sharp & Dohme GmbH

SL-MSD

For more than 125 years, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. Today, MSD continues to be at the forefront of research to prevent and treat diseases that threaten people and animals.

Silver Sponsor

Agendia

SL-Agendia-mp-bp

Agendia is a leading precision oncology company that develops genomic tests to support physicians faced with complex treatment decisions. MammaPrint®, the 70-gene signature is an FDA-cleared breast cancer recurrence assay, backed by peer-reviewed, prospective data and included in many guidelines. BluePrint®, the 80-gene molecular subtyping assay looks beyond the cell surface to identify Luminal-type, Basal-type and HER2-type breast cancer.

Natera

SL-Natera

Discover the latest advantages of using a personalized, tumor-informed circulating tumor DNA (ctDNA) test to design oncology clinical trials in Breast Cancer.  Signatera, a breakthrough technology, can be applied in early stage and late stage cancer trials, potentially enriching for patients most likely to respond to therapy, accelerating time to trial readout, or identifying early relapsers.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings